



Image 1648

TMH:dv 2/13/04 6395-64908
I-001-01/0

PATENT
Attorney Reference Number 6395-64908

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Chang

Application No. 09/826,115

Filed: April 4, 2001

Confirmation No. 4134

For: NUCLEIC ACID VACCINES FOR
PREVENTION OF FLAVIVIRUS
INFECTION

Examiner: Jeffrey S. Parkin

Art Unit: 1642

Attorney Reference No. 6395-64908

COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Attorney
for Applicant(s)

Tanya M. Harding, Ph.D.

Date Mailed February 10, 2004

TRANSMITTAL LETTER

Enclosed for filing in the application referenced above are the following:

- ☒ Information Disclosure Statement
- ☒ Form 1449 and references cited thereon (4)
- ☒ The Director is hereby authorized to charge any additional fees that may be required, or credit over-payment, to Deposit Account No. 02-4550. A copy of this sheet is enclosed.
- ☒ Please return the enclosed postcard to confirm that the items listed above have been received.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By

Tanya M. Harding, Ph.D.
Registration No. 42,630

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 226-7391
Facsimile: (503) 228-9446
cc: Docketing



TMH: 02/10/04 6395-64908 I-001-01/1

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Chang

Application No. 09/826,115

Filed: April 4, 2001

Confirmation No. 4134

For: NUCLEIC ACID VACCINES FOR
PREVENTION OF FLAVIVIRUS INFECTION

Examiner: Jeffrey S. Parkin

Art Unit: 1642

Attorney Reference No. 6395-64908

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Attorney
for Applicant(s)

Tanya M. Harding, Ph.D.

Date Mailed February 10, 2004

INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. § 1.97(b)(3)

COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

Listed on the accompanying form PTO-1449 and enclosed herewith are four English-language documents. Applicant respectfully requests that these documents be listed as references cited on the issued patent.

Applicant are filing this Information Disclosure Statement ("IDS") before the mailing date of a first Office action on the merits. As a result, no fee should be required to file this IDS. It is believed that no fee is due to file this IDS. If the Commissioner determines that a fee is due, Deposit Account authority is provided on the accompanying transmittal letter.

The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By

Tanya M. Harding, Ph.D.
Registration No. 42,630

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 226-7391; Facsimile: (503) 228-9446



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

| | |
|-------------------------------|-------------------|
| Attorney Docket Number | 6395-64908 |
| Application Number | 09/826,115 |
| Filing Date | April 4, 2001 |
| First Named Inventor | Chang |
| Art Unit | 1642 |
| Examiner Name | Jeffrey S. Parkin |

| Examiner's Initials* | Cite No. (optional) | OTHER DOCUMENTS |
|-------------------------|------------------------|---|
| | | Chang <i>et al.</i> , "Enhancing biosynthesis and secretion of premembrane and envelope proteins by the chimeric plasmid of dengue virus type 2 and Japanese encephalitis virus," <i>Virology</i> , 306:170-180, 2003. |
| | | Chang <i>et al.</i> , "Flavivirus DNA Vaccines," <i>Annals New York Academy of Sciences</i> , 272-285 |
| | | Davis <i>et al.</i> , "West Nile Virus Recombinant DNA Vaccine Protects Mouse and Horse from Virus Challenge and Expresses In Vitro a Noninfectious Recombinant Antigen That Can Be Used in Enzyme-Linked Immunosorbent Assays," <i>J. Virology</i> , 75(9):4040-4047, May 2001 |
| | | Hunt <i>et al.</i> , "A recombinant particulate antigen of Japanese encephalitis virus produced in stably-transformed cells is an effective noninfectious antigen and subunit immunogen," <i>J. Virological Methods</i> , 97:133-149, 2001 |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |

EXAMINER
SIGNATURE:

DATE
CONSIDERED:

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.